23I Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Intra-Cellular Therapies Inc

Watchlist Manager

Watchlist

Price: 122 EUR 0.83% Market Closed

Market Cap: €12.9B

I	Intra-Cellular Therapies Inc F:23I	US

Profitability Summary

Intra-Cellular Therapies Inc's profitability score is 26/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

92%

Strong 3Y Average Gross Margin

92%

Declining Gross Margin

93% > 92%

Negative Operating Margin

-17%

Negative 3Y Average Operating Margin

-23%

Operating Margin is Increasing

-41% > -17%

Negative Net Margin

-11%

Negative 3Y Average Net Margin

-18%

Net Margin is Increasing

-37% > -11%

Negative Free Cash Flow Margin

-11%

Negative 3Y Average Free Cash Flow Margin

-16%

Free Cash Flow Margin is Increasing

-38% > -11%

Negative ROE

-9%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-57%

ROIC is Increasing

-98% > -42%

View All

Hide

Collapse

26 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.